BriaCell Therapeutics Corp. (OTCMKTS:BCTXF – Get Free Report)’s stock price fell 3.9% during mid-day trading on Wednesday . The company traded as low as $0.56 and last traded at $0.57. 400,683 shares changed hands during mid-day trading, an increase of 21,454% from the average session volume of 1,859 shares. The stock had previously closed at $0.60.
BriaCell Therapeutics Stock Up 5.4 %
The company has a 50-day moving average price of $0.78 and a 200-day moving average price of $1.00. The company has a market capitalization of $464,975.60, a price-to-earnings ratio of -0.15 and a beta of 1.09.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- There Are Different Types of Stock To Invest In
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- What is Insider Trading? What You Can Learn from Insider Trading
- Williams-Sonoma Stock: Buy It and Never Let It Go
- 5 discounted opportunities for dividend growth investors
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
